Phytopharm of the UK has started a proof-of-principle study of P57, itsstandardized botanical-based drug which is being developed as an appetite suppressant to treat obesity. The residential study will involve up to 62 healthy male volunteers and will evaluate the safety, tolerability and pharmacokinetic profile of P57, as well as looking at its effect on calorie intake.
The first two stages of the study will look at ascending single doses of P57, as well as repeat dosing in overweight subjects, and data from these will be used to select a dose and regimen for a final stage looking at a 15-day regimen. P57 is licensed to Pfizer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze